George Clinical, a clinical research organization (CRO) based in both the Asia-Pacific and the US, and Asia-based CRO EPS International (EPSI) have entered a strategic partnership to deliver clinical trial services to clients in Japan and the Asia-Pacific region.
Per the partnership, George Clinical will provide clinical trial services for EPSI and its Japanese customers across Asia, the US, and Europe.
The companies will work together to provide clinical trial operating capability across the Asia-Pacific region. In China, however, both EPSI and George will both maintain an independent operating presence.
Glen Kerkhof, executive chairman of George Clinical said in a statement that the Asia-Pacific region is the third largest pharmaceutical market in the world, and the partnership will give the company the capability to manage clinical trials across the growing network.
“As the region has developed into a sophisticated and desirable clinical trial location, so too has George Clinical developed into a highly-adaptable and scientifically led CRO, both regionally and globally,” said Kerkhof.
Neither EPSI nor George Clinical were able to respond to our request for comment.
